Abstract:Various immune checkpoint inhibitors such as anti-programmed cell death protein 1 antibody (αPD-1) have been used in the clinic, but the associated low response rate and high incidence of side effects have hindered their further use. Gut microbiota has been widely identified as a potential adjunct to sensitizing immunotherapy.1 The microbial composition of faeces varies in patients with different sensitivities to immunotherapy, and the efficacy of immunotherapy can be influenced by faecal microbiota transplantation or supplementation with specific strains. We recently reported in Cell that a gut microbiota derivative, indole-3-propionic acid (IPA), increases the responsiveness of cancer immunotherapy by modulating T-cell stemness.2 We first identified the 'Responder' and the 'Poor-responder' mice in mice receiving immunotherapy similar to clinical practice. The gut microbiota of these mice was found to be different by microbiome sequencing, leading us to speculate that gut microbiota might be involved in cancer immunotherapy response. We also found that mice transplanted with the 'Poor-responder' faeces were less responsive to immunotherapy and screened a strain of Lactobacillus johnsonii (L. johnsonii) (Figure 1A). Gavage administration of L. johnsonii to mice increased CD8+ T cell infiltration to sensitize the efficacy of αPD-1 therapy. A growing number of specific gut strains have been shown to play a role in immunotherapy, but they act with different components, some through their own bacterial components and others through secreted metabolites.3-5 There is a lack of specific means and standardized procedures to reveal the exact components of bacterial action. We used different treatments to investigate the active components of L. johnsonii. Compared with heat-inactivated and ultrasonically fragmented bacteria, the culture supernatant of L. johnsonii had an effect similar to that of live bacteria, suggesting that L. johnsonii colonized in the gut may secrete relevant metabolites into the blood. In combination with non-targeted plasma metabolic mass spectrometry and the tryptophan-deficient diet, we identified a key indole derivative: IPA. Gavage of IPA also enhanced the efficacy of αPD-1 by increasing CD8+ T cell infiltration and effector secretion. As an essential amino acid, tryptophan is metabolized by three main pathways: the 5-hydroxytryptamine pathway, the kynurenine pathway and the indole pathway. Of these, the indole pathway is relatively unique in that it is mainly carried out by intestinal microorganisms.6 The gut microbiota genome contains a large number of unknown metabolic enzyme gene clusters that are capable of performing a wide range of metabolic reactions that cannot be performed by the host alone. A number of specific bacteria, such as Lactobacillus, Bifidobacterium and Clostridium, have been identified as containing key enzymes that stepwise breakdown tryptophan into a variety of indole derivatives.7 Recent studies have also focused on the role of indole derivatives in regulating the physiological functions of organs and in the development of disease. Among these, IPA has been shown to promote nerve regeneration and repair,8 prevent ejection fraction and heart failure,9 and prolong survival in rats with traumatic colon injury,10 but its role in cancer immunotherapy has not yet been clarified. We further used Rag1−/− mice, anti-CD8 neutralizing antibody, and adoptive cell transfer therapy to validate the sensitizing immunotherapeutic effects of L. johnsonii and its derived IPA dependent on CD8+ T cells, and sorted CD8+ T cells infiltrated in tumours of mice for single-cell RNA sequencing (scRNA-seq), single-cell TCR sequencing (scTCR-seq) and single-cell assay for targeting accessible-chromatin with high-throughout sequencing (scATAC-seq). Gavage IPA significantly increased the proportion of 'stem cell-like' progenitor-exhausted CD8+ T (Tpex) cells and effector CD8+ T cells. These two subsets of CD8+ T cells shared TCR profiles and underwent clonal expansion. Combined with single-cell transcriptomic pathway enrichment and scATAC-seq, we found that IPA regulates chromatin opening in Tpex cells through histone acetylation modifications. Western blot, ChIP, CUT & RUN and CUT & Tag sequencing further revealed that IPA increases H3K27 acetylation in the Tcf7 super-enhancer region. Recent studies have shown that Tpex cells with high expression of the transcription factor T-cell factor 1 (TCF-1, encoded by TCF7) and immunocyte stemness properties are a key subset responding to immunotherapy with anti-PD-1 antibodies.11 Further activation of Tpex cells to increase immune cell stemness could be an important strategy to improve the efficacy of immunotherapy. Tcf7 knockout mice are associated with an imbalance in gut microbiota,12 but the ability of specific strains and their metabolites to modulate the immunocyte stemness has not been reported. Here, we found that bacterial-derived IPA has the potential to regulate T-cell stemness and Tcf7−/− mice verified that IPA requires Tpex cells for sensitizing immunotherapeutic effects. We then explored how L. johnsonii produces IPA. Interestingly, IPA was not detected in L. johnsonii culture supernatants in vitro, but instead, the upstream metabolite of IPA, indole-3-lactic acid (ILA) was detected. Based on the antibiotic cocktail model and intraperitoneal injection model, we hypothesized that ILA produced by L. johnsonii is further metabolized to IPA by other gut microbiota in vivo and verified this in germ-free mice model. Colonization of germ-free mice with L. johnsonii alone produces only ILA, whereas mixed administration of L. johnsonii and Clostridium sporogenes, produces large amounts of IPA, sensitizing the efficacy of immunotherapy. The intestinal microbiota can be regarded as a small society, the members of which are combined in a certain proportion, mutually restrained, dependent on each other, and form a kind of ecological equilibrium both qualitatively and quantitatively. Many bacterial metabolites are not produced by a single bacterium, and there is complex cooperation and competition between gut microbes at the genus level, at the species level, and even between strains. Recent publications have focused on the synthetic processing of metabolites by means of cooperation between bacteria. C. scindens cooperates with its related strain to convert primary bile acids to secondary bile acids.13 Bacteroides cooperate with Lactobacillus plantarum to metabolize host tyrosine.14 We provide an additional paradigm that L. johnsonii and Clostridium sporogenes could work together to metabolize tryptophan to biosynthesize IPA (Figure 1B). We also predicted that ldhA was the key enzyme for ILA production by L. johnsonii and transformed a ldhA expressional vector into E. coli. E. coli overexpressing ldhA increased IPA production and sensitized immunotherapeutic effects. Finally, we verified the regulatory effects of IPA on Tpex cells and immunotherapy in a variety of mouse tumour models (both breast cancer and melanoma transplantable tumour model, mammary fat pad orthotopic implantation model, MMTV-PyMT spontaneous breast cancer model and cecum orthotopic implantation model) and in organoids derived from colorectal cancer patients (Figure 1C). In summary, this work reveals a tryptophan derivative cooperatively produced by different bacteria, elucidates the mechanism by which IPA regulates key transcription factors of immune stemness through histone acetylation modifications, and validates the sensitizing immunotherapeutic effects of IPA at the pan-cancer level. This bacterial-derived metabolite-host immunomodulatory pathway provides a potential idea for sensitizing cancer immunotherapy. For future clinical applications of gut microbiota, it is necessary to consider the ability of bacteria to colonize efficiently and produce metabolites in a sustained manner. Particularly for non-native bacteria, it may be necessary to construct engineered bacteria by homologous recombination to achieve efficient metabolite synthesis. Recent publications have also highlighted the potential of gut microbes to mitigate adverse effects associated with immune checkpoint inhibitors,15, 16 which is likely to be a future research trend. Overall, although larger, multi-centre clinical trials are needed to clarify the role of the gut microbiota in cancer immunotherapy, it certainly has a promising future. Writing—Original Draft, Dingjiacheng Jia; Writing—Review & Editing, Liangjing Wang. Not applicable. The authors declare no conflict of interest. The National Foundation of Natural Science of China (82273269 to L.-J.W.). Not applicable.

Abstract:In recent publications,1, 2 the group of Professor Zhu Shu/Pan Wen and the research team of Wang Liangjing/Chen Shujie, respectively investigated two intestinal microbial metabolites: deoxycholic acid (DCA) and indole-3-propionic acid (IPA). DCA acts on the calcium ion channel plasma membrane Ca2+ ATPase (PMCA), inhibits the effector function of CD8+ T cells and consequently promotes colorectal cancer (CRC) growth. IPA activates precursor-exhausted T (Tpex) cells and induces their transformation into effector T (Teff) cells, thereby increasing T-cell infiltration into the tumor tissue and enhancing the efficacy of immunotherapy (Figure 1). Zhu et al. screened 73 small-molecule compounds derived from microbial sources to examine their effects on CD8+ T-cell-mediated cytotoxicity or IFN-γ production, and identified DCA. Subsequent experiments using sodium dodecyl sulfate (SDS) or other chemical inhibitors confirmed that DCA does not lead to cell death. In tumor immunity, CD8+ T cells are crucial in resisting tumors, with cytokines such as IFN-γ and TNF-α playing key roles in killing tumor cells. CD8+ T-cell activation relies on Ca2+ as a second messenger and the cytoplasmic Ca2+ concentration directly affects CD8+ T-cell activation. The authors found that DCA could inhibit cytoplasmic Ca2+ accumulation by monitoring the real-time fluorescence intensity of cytoplasmic Ca2+ in anti-CD3/CD28-activated CD8+ T cells. NFAT2 is an important transcription factor regulating CD8+ T cells.3 According to immunoblotting results, DCA reduced the transcription of this factor. Using NFAT2-luciferase reporter gene assays, the authors observed that PMA/ionomycin stimulation increased the transcriptional activity of NFAT2. Notably, DCA supplementation attenuated this transcriptional activation, indicating that DCA could inhibit the NFAT2-mediated transcription induced by Ca2+ influx. To further study the specific effects of DCA, the authors examined several key observations. First, DCA did not reduce the levels of free calcium ions in cell-free culture medium, indicating that DCA does not chelate calcium ions. Second, the calcium-release activated channel (CRAC) was the main inward pathway. The immunosuppressive impact of DCA on CD8+ T cells persisted despite the presence of the selective CRAC channel blocker, BTP2, indicating that DCA did not affect calcium influx. Third, PMA/ionomycin induces Ca2+ to be released directly from the endoplasmic reticulum without relying on transporter proteins.1, 4 However, DCA inhibits Ca2+ accumulation, indicating that Ca2+ may flow out of the cell membrane in large quantities or into intracellular stores. Therefore, having blocked various channels known to suppress cytoplasmic Ca2+ levels, the authors found that DCA inhibits cytoplasmic Ca2+ accumulation by enhancing PMCA-mediated Ca2+ efflux, and validated this using a PMCA inhibitor. However, research into the precise binding site of DCA on PMCA remains limited. Further research is required to elucidate the mechanism by which DCA boosts PMCA activity. The authors have proposed a possible therapeutic strategy based on the mechanism of DCA. They isolated a bacteriophage from urban sewage that targets the lysis of C. scindens. This bacteriophage effectively reduces the serum DCA concentration, alleviates tumor growth, and enhances the effector function of CD8+ T cells, thereby presenting a potential therapeutic avenue for CRC.1 Additionally, in previous experiments, the use of the inhibitor LaCl3, or interference with shPMCA, inhibited PMCA, similarly alleviating the inhibition of CD8+ T cells. PMCA inhibitors may be used as an adjuvant therapy for those patients with high DCA-producing bacteria. Zhu et al.'s research highlights the enhancement of CD8+ T cell activity as a pivotal aspect of immunotherapy strategies. Wang et al. found that IPA enhances the activity of CD8+ T cells. They conducted in-depth research on the mechanism by which IPA improves tumor responsiveness to immune checkpoint blockade (ICB). These studies provide a conceptual basis for an adjunct approach to cancer treatment. Wang et al. analyzed microbial community differences by dividing mice into poor-responder group and responder group according to αPD-1 therapy. At the species level, Lactobacillus johnsonii exhibited the largest differences. This is consistent with findings in human CRC tissues, where the abundance of this bacterium was negatively correlated with tumor progression. To further investigate the effects of specific substances, the authors grouped mice and treated them with different culture media containing various bacteria. The results showed that only treatment with L. johnsonii-conditioned medium (Lj.CM) had a good therapeutic effect on tumors, comparable to direct oral administration of L. johnsonii. Moreover, the authors found that the levels of tryptophan-related metabolites, especially IPA, a tryptophan-derived metabolite specific to the intestinal microbiota, were increased in the plasma of mice. Surprisingly, only indole-3-lactate (ILA), a precursor substance that can be converted to IPA, was detected in Lj.CM medium, rather than IPA. Subsequent experiments confirmed that the production of IPA requires the cooperation of L. johnsonii and C. sporogenes.2 To determine whether the action of this substance depends on T cells, the authors transferred IPA or L. johnsonii to immunodeficient mice. Both treatments didn't reduce the growth of tumor. Then, IPA-untreated CD8+ T cells or IPA-pretreated CD8+ T cells was administered to the mice. The authors found that the CD8+ T cell group pretreated with IPA showed better tumor suppression compared to the group without IPA, proving that IPA acts through T cells. In subsequent studies using techniques such as single-cell RNA sequencing and single-cell T-cell receptor sequencing, the authors examined the group treated with αPD-1 alone or the IPA group treated with IPA and αPD-1 in combination therapy. The results revealed that IPA diminished naive CD8+ T cell populations, but augmented the population of Tpex cells which characterized by high TCF1 expression, and promoted the conversion of Tpex cells to Teff cells, thereby enhancing the responsiveness to ICB.2 The authors mapped the results of scRNA-seq to those of scATAC-seq and found that IPA activates Tpex cells by modifying the H3K27 acetylation of the Tcf7 super-enhancer region. Based on these results, the authors simulated the tumor microenvironment in CRC tissues. They found that IPA treatment increased CD8+ T cell infiltration and TCF-1 expression in tumors, effectively improving the efficacy of αPD-1 immunotherapy. However, more investigations are required to validate the feasibility of employing IPA as an adjunct immunotherapeutic agent. In conclusion, two research teams discovered the effects of microbial metabolites in the tumor microenvironment by studying the intestinal microbiota. These two studies provided relevant results from different perspectives on tumor immunity. These discoveries offered potential solutions and research directions for promoting the responsiveness of certain tumors to immunotherapy. Mingyan Zhang wrote the manuscript and prepared the figure. Feng Xie provided valuable discussion. Fangfang Zhou approved the final version of the manuscript. All authors have read and approved the final manuscript. This work was supported by the Chinese National Natural Science Funds (92169122, 32125016) and a project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. The authors declare no conflicts of interest. The authors have nothing to report. The authors have nothing to report.

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Modulating Commensal Bacteria to Intervene in Cancer Immunotherapy

Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite

The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Hexa-acylated lipopolysaccharides from the gut microbiota enhance cancer immunotherapy responses

The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

Abstract 3733: Gut microbiota-dependent bile acidtaurodeoxycholic acid, TDCAfacilitates anti-tumor immune responses by modulating cytotoxic CD8 T cell immunity

Association of microbial metabolism of tryptophan with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC).

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

The Impact of Intestinal Microbiota‐derived Metabolites on Cancer and Their Potential Application in Tumor Immunotherapy

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors

841P Effects of Immune Checkpoint Inhibitor-Based Combination Therapies on the Gut Microbiota in Advanced Melanoma Patients

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Abstract 6673: Tumor microbial burden is regulated by mast cells and determines immunotherapy responses

Effect of Indole 3-Propionic Acid from Microbiota on the Immunity of CD8+ T Cell to Improve Chemotherapy of Colorectal Cancer.